Anoctamin-5 related muscle disease: clinical and genetic findings in a large European cohort
Brain · 01.09.2023 · 146 (9) · 3800-3815
DOI: 10.1093/brain/awad088 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Brain, online erschienen am 13.03.2023. Verfasst von Alexander de Bruyn und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium. Hauptthemen laut MEDLINE: Muscular Diseases, Muscular Dystrophies, Limb-Girdle. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Anoctamin-5 related muscle disease is caused by biallelic pathogenic variants in the anoctamin-5 gene (ANO5) and shows variable clinical phenotypes: limb-girdle muscular dystrophy type 12 (LGMD-R12), distal muscular dystrophy type 3 (MMD3), pseudometabolic myopathy or asymptomatic hyperCKaemia. In this retrospective, observational, multicentre study we gathered a large European cohort of patients with ANO5-related muscle disease to study the clinical and genetic spectrum and genotype–phenotype correlations. We included 234 patients from 212 different families, contributed by 15 centres from 11 European countries. The largest subgroup was LGMD-R12 (52.6%), followed by pseudometabolic myopathy (20.5%), asymptomatic hyperCKaemia (13.7%) and MMD3 (13.2%). In all subgroups, there was a male predominance, except for pseudometabolic myopathy. Median age at symptom onset of all patients was 33 years (range 23–45 years). The most frequent symptoms at onset were myalgia (35.3%) and exercise intolerance (34.1%), while at last clinical evaluation most frequent symptoms and signs were proximal lower limb weakness (56.9%) and atrophy (38.1%), myalgia (45.1%) and atrophy of the medial gastrocnemius muscle (38.4%). Most patients remained ambulatory (79.4%). At last evaluation, 45.9% of patients with LGMD-R12 additionally had distal weakness in the lower limbs and 48.4% of patients with MMD3 also showed proximal lower limb weakness. Age at symptom onset did not differ significantly between males and females. However, males had a higher risk of using walking aids earlier (P = 0.035). No significant association was identified between sportive versus non-sportive lifestyle before symptom onset and age at symptom onset nor any of the motor outcomes. Cardiac and respiratory involvement that would require treatment occurred very rarely. Ninety-nine different pathogenic variants were identified in ANO5 of which 25 were novel. The most frequent variants were c.191dupA (p.Asn64Lysfs*15) (57.7%) and c.2272C>T (p.Arg758Cys) (11.1%). Patients with two loss-of function variants used walking aids at a significantly earlier age (P = 0.037). Patients homozygous for the c.2272C>T variant showed a later use of walking aids compared to patients with other variants (P = 0.043). We conclude that there was no correlation of the clinical phenotype with the specific genetic variants, and that LGMD-R12 and MMD3 predominantly affect males who have a significantly worse motor outcome. Our study provides useful information for clinical follow up of the patients and for the design of clinical trials with novel therapeutic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.
- Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University of Munich, 80336 Munich, Germany.
- Copenhagen Neuromuscular Center (CNMC), Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.
- Reference Center for Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
- Neuromuscular Center, Department of Neurology, Tampere University Hospital, 33520 Tampere, Finland.
- Neurocenter, Department of Neurology, Clinical Neurosciences, Turku University Hospital and University of Turku, 20014 Turku, Finland.
ORCID-Profile: Federica Montagnese, Tanya Stojkovic
Zitieren
APA
de Bruyn, A., Montagnese, F., Holm-Yildiz, S., Scharff Poulsen, N., Stojkovic, T., Behin, A., Palmio, J., Jokela, M., De Bleecker, J. L., de Visser, M., van der Kooi, A. J., Ten Dam, L., Domínguez González, C., Maggi, L., Gallone, A., Kostera-Pruszczyk, A., Macias, A., Łusakowska, A., Nedkova, V., …, & Claeys, K. G. (2023). Anoctamin-5 related muscle disease: clinical and genetic findings in a large European cohort. Brain, 146(9), 3800-3815. https://doi.org/10.1093/brain/awad088
Vancouver
de Bruyn A, Montagnese F, Holm-Yildiz S, Scharff Poulsen N, Stojkovic T, Behin A, et al. Anoctamin-5 related muscle disease: clinical and genetic findings in a large European cohort. Brain. 2023;146(9):3800-3815. doi:10.1093/brain/awad088
BibTeX
@article{deBruyn2023,
author = {de Bruyn, Alexander and Montagnese, Federica and Holm-Yildiz, Sonja and Scharff Poulsen, Nanna and Stojkovic, Tanya and Behin, Anthony and Palmio, Johanna and Jokela, Manu and De Bleecker, Jan L and de Visser, Marianne and van der Kooi, Anneke J and Ten Dam, Leroy and Domínguez González, Cristina and Maggi, Lorenzo and Gallone, Annamaria and Kostera-Pruszczyk, Anna and Macias, Anna and Łusakowska, Anna and Nedkova, Velina and Olive, Montse and Álvarez-Velasco, Rodrigo and Wanschitz, Julia and Paradas, Carmen and Mavillard, Fabiola and Querin, Giorgia and Fernández-Eulate, Gorka and Quinlivan, Ros and Walter, Maggie C and Depuydt, Christophe E and Udd, Bjarne and Vissing, John and Schoser, Benedikt and Claeys, Kristl G},
title = {Anoctamin-5 related muscle disease: clinical and genetic findings in a large European cohort},
journal = {Brain},
year = {2023},
volume = {146},
number = {9},
pages = {3800--3815},
doi = {10.1093/brain/awad088}
}
EUVIMED